Jefferies downgraded Reneo Pharmaceuticals to Hold from Buy with a price target of $1.80, down from $17. The company’s’ sole asset mavodelpar failed to show clinical benefits distinguishable from placebo in a rare mitochondrial disease, resulting in program suspension and a 70% workforce reduction, the analyst tells investors in a research note. The firm says Reneo will provide details on its next step in January.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on RPHM:
- Reneo Pharmaceuticals just downgraded at Leerink, here’s why
- Reneo Pharmaceuticals just downgraded at Ladenburg, here’s why
- Reneo Pharmaceuticals just downgraded at Piper Sandler, here’s why
- Reneo Pharmaceuticals just downgraded at BofA, here’s why
- Reneo Pharmaceuticals just downgraded at William Blair, here’s why